Pharmaceuticals & Biotech

Pipelines, trials, approvals, safety, manufacturing, and next‑gen therapies.

  • 7 Subtopics
  • 9 Tracked terms
  • Last 30 days Feed window
Search within this topic Ask AI about this topic All topics

Inside Pharmaceuticals & Biotech

Discovery & Preclinical Targets, assays, animal models, and early safety/tox studies before human trials. Clinical Trials (Phases I–IV) Design, endpoints, enrollment, interim reads, and post‑market surveillance. Approvals, Safety & REMS FDA/EMA decisions, boxed warnings, pharmacovigilance, and label changes. Generics & Biosimilars Access, interchangeability, litigation, and pricing dynamics for follow‑ons. Vaccines & Immunization Platforms (mRNA, viral vector), boosters, schedules, and cold‑chain supply. Cell & Gene Therapies CAR‑T, CRISPR, in vivo delivery, manufacturing, and long‑term follow‑up. Manufacturing & Supply APIs, sterile fill‑finish, shortages, and quality systems across the supply chain.

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Pharmaceuticals & Biotech


wiod.iheart.com > featured > florida-news > content > 2026-09-19-florida-may-let-pharmacists-give-chikungunya-vaccines

Florida May Let Pharmacists Give Chikungunya Vaccines | NewsRadio WIOD

4+ hour, 17+ min ago   (263+ words) FLORIDA - Florida health officials are considering a rule change that would expand access to chikungunya vaccination through pharmacies. The Florida Department of Health has proposed adding the chikungunya vaccine to the list of immunizations qualified pharmacists may administer. The Florida…...


smanewstoday.com > news > sma-children-experiencing-symptoms-show-motor-gains-following-gene-therapy

SMA children with symptoms show motor gains after gene therapy

19+ min ago   (713+ words) But findings of real-world study emphasize importance of early diagnosis Written by Andrea Lobo | Sept. 21, 2026 Children with spinal muscular atrophy (SMA) already living with symptoms experienced gains in motor abilities after receiving the gene therapy Zolgensma (onasemnogene abeparvovec-xioi), a small…...


krocnews.com > ixp > 717 > p > sensory-friendly-vaccine-clinic-omc-rochester

A Sensory-Friendly Vaccine Clinic is Being Offered in Rochester Again this Year

24+ min ago   (258+ words) Getting a vaccine can be stressful, but this annual clinic at OMC can help with that. For the fourth year in a row, Olmsted Medical Center will be offering a one day only sensory-friendly vaccine clinic. I think this is…...


losbanosenterprise.com > health-and-wellness > 2026 > some-valley-schools-see-kindergarten-vaccine-rates-for-measles-fall-short-of-herd-immunity

Some Valley schools see kindergarten vaccine rates for measles fall short of ‘herd immunity’

57+ min ago   (941+ words) Amid conflicting messages over the safety of vaccines, cases of measles have been on the rise both in California and the U.S. this year compared to 2025. And in the San Joaquin Valley, where two cases of measles have been reported so…...


biospace.com > deals > western-licensing-deals-for-chinese-radioligand-therapies-to-jump-in-2027-sleuth-forecasts

Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts

35+ min ago   (256+ words) Next year will bring a significant rise in deals between Chinese radioligand therapy developers and companies capable of supplying the drugs in the West, according to biopharma intelligence platform Sleuth. Sleuth predicts 2027 will be the year that Western in-licensing of…...


www2.ljworld.com > news > state-region > 09/21/2026 > kansas-reports-first-measles-cases-of-the-year-as-vaccination-rates-decline

Kansas reports first measles cases of the year, as vaccination rates decline

1+ hour, 43+ min ago   (310+ words) Sep 21, 2026 - 12:04pm Different vials of triple viral vaccine of measles, rubella and mumps, known as MMR, are pictured. TOPEKA — Kansas joined a growing list of states nationwide reporting measles cases with two cases apparently related to travel outside the state, a…...


newmediawire.com > news > geovax-next-generation-mva-vaccine-demonstrates-durable-single-dose-protection-in-preclinical-models-7089829

GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models

5+ hour, 15+ min ago   (215+ words) Study Shows Protection Against Highly Pathogenic Clade I Mpox Virus and Durable CD8+ T-Cell Responses Findings Support GeoVax’s Broader Strategy to Expand the Utility of the MVA Vaccine Platform The research was conducted in collaboration with investigators at Washington State University…...


adnkronos.com > immediapress > eng > menarini-group-and-newamsterdam-pharma-receive-european-commission-approval-for-ubeslo-obicetrapib-monotherapy-and-evlarco-obicetrapib-plus-ezetimibe-fixed-dose-combination_7qj9sMsGFeEl61WyPkAEDH

Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

1+ hour ago   (1026+ words) Adnkronos - First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile - - First global regulatory approval of obicetrapib marks a defining milestone for NewAmsterdam and Menarini, expanding treatment options for patients with elevated…...


raps.org > resource > recon-fda-staff-raise-no-major-concerns-for-grail-multi-cancer-test-ahead-of-adcomm-trump-admin-drafting-order-to-exert-control-over-nih-grant-funding.html

Recon: FDA staff raise no major concerns for Grail multi-cancer test ahead of adcomm; Trump admin drafting order to exert control over NIH grant funding

1+ hour, 7+ min ago   (94+ words) The complete guide to formulating an effective global regulatory strategy for medical devices, created and curated by experts. Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories…...


multiplesclerosisnewstoday.com > news-posts > 09/21/2026 > tiziana-inks-deal-trial-test-experimental-treatment-rrms

Tiziana inks deal for trial to test its experimental treatment in RRMS

3+ hour, 29+ min ago   (464+ words) Nasal therapy foralumab will be tested in combination with anti-CD20 therapy Written by Marisa Horak, MS | Sept. 21, 2026 Tiziana Life Sciences has signed a deal with strategic partners to support a clinical trial designed to test its experimental nasal therapy foralumab…...